 | |
| Names | |
|---|---|
| Preferred IUPAC name 7-Chloro-4-oxo-1,4-dihydroquinoline-2-carboxylic acid | |
| Other names 7-Chlorokynurenate; 7-CTKA | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| ECHA InfoCard | 100.038.088 |
| UNII | |
| |
| Properties | |
| C10H6ClNO3 | |
| Molar mass | 223.61 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
7-Chlorokynurenic acid (7-CKA) is atool compound that acts as a potent and selectivecompetitive antagonist of theglycine site of theNMDA receptor.[1] It producesketamine-like rapidantidepressant effects inanimal models ofdepression.[2][3] However, 7-CKA is unable to cross theblood-brain-barrier, and for this reason, is unsuitable forclinical use.[4] As a result, acentrally-penetrantprodrug of 7-CKA,4-chlorokynurenine (AV-101), has been developed for use in humans, and is being studied inclinical trials as a potential treatment formajor depressive disorder,[4][5][6] and anti-nociception.[7] In addition to antagonizing the NMDA receptor, 7-CKA also acts as a potentinhibitor of thereuptake ofglutamate intosynaptic vesicles (or as avesicularglutamate reuptake inhibitor), an action that it mediates viacompetitive blockade ofvesicular glutamate transporters (Ki = 0.59 mM).[8]
